Sorrento Therapeutics Inc Revenue Growth Rates (SRNEQ), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sorrento Therapeutics Inc   (SRNEQ)
 

SRNEQ's Revenue Growth by Quarter and Year

Sorrento Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SRNEQ Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June 15.03
1st Quarter March 16.25
FY 31.28

SRNEQs Annual Revenue
Sorrento Therapeutics Inc 's Revenue in the fiscal year 2022 $ 62.84 millions
Sorrento Therapeutics Inc 's Revenue in the fiscal year 2021 $ 52.90 millions
Sorrento Therapeutics Inc 's Revenue in the fiscal year 2020 $ 39.99 millions
Sorrento Therapeutics Inc 's Revenue in the fiscal year 2019 $ 31.43 millions
Sorrento Therapeutics Inc 's Revenue in the fiscal year 2018 $ 21.19 millions




SRNEQ Revenue second quarter 2023 Y/Y Growth Comment
Sorrento Therapeutics Inc reported Revenue improvement of 31.11% year on year in the second quarter 2023, to $ 15.03 millions, this is lower than Sorrento Therapeutics Inc 's recent average Revenue surge of 223.14%.

Looking into second quarter 2023 results within Biotechnology & Pharmaceuticals industry 27 other companies have achieved higher Revenue growth. While Sorrento Therapeutics Inc ' s Revenue rise of 31.11% ranks overall at the positon no. 752 in the second quarter 2023.


SRNEQ Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 19.19 % 13.64 % -11.67 %
3rd Quarter September - 44.28 % 2.64 % 103.29 %
2nd Quarter June 31.11 % -15.17 % 49.94 % 39.04 %
1st Quarter March -11.64 % 28.96 % 84.72 % 25.73 %
FY   - 18.77 % 32.31 % -

Financial Statements
Sorrento Therapeutics Inc 's second quarter 2023 Revenue $ 15.03 millions SRNEQ's Income Statement
Sorrento Therapeutics Inc 's second quarter 2022 Revenue $ 11.46 millions Quarterly SRNEQ's Income Statement


SRNEQ Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - -10.4 % 8.46 % -2.04 %
3rd Quarter September - 51.83 % -10.73 % 30.41 %
2nd Quarter June -7.54 % -37.68 % -5.26 % 16.71 %
1st Quarter March 4.23 % 40.6 % 23.89 % -40.75 %
FY (Year on Year)   - 18.77 % 32.31 % -


Back to SRNEQ Growth rate Comparisons >> Back to SRNEQ Growth rate Comparisons >>


Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #28
Healthcare Sector #205
Overall #752

Revenue Y/Y Growth Statistics
High Average Low
5335.13 % 223.14 % -96.63 %
(Sep 30 2017)   (Dec 31 2022)
Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #28
Healthcare Sector #205
Overall #752
Revenue Y/Y Growth Statistics
High Average Low
5335.13 % 223.14 % -96.63 %
(Sep 30 2017)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Sorrento Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
148.67 % 4.62 % -100 %
(Sep 30 2016)  


SRNEQ's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Sorrento Therapeutics Inc disclosed drop in Revenue from the first quarter by -7.54% to $ 15.03 millions, from $ 16.25 millions achived in the previous reporting period.

But that's not important problem, as Sorrento Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Sorrento Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3314.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #54
Healthcare Sector #510
Overall #3314
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #54
Healthcare Sector #510
Overall #3314
Revenue Q/Q Growth Statistics
High Average Low
148.67 % 4.62 % -100 %
(Sep 30 2016)  


SRNEQ's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Sorrento Therapeutics Inc disclosed drop in Revenue from the first quarter by -7.54% to $ 15.03 millions, from $ 16.25 millions achived in the previous reporting period.

But that's not important problem, as Sorrento Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Sorrento Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3314.


Sorrento Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 64.27 $ 60.71 $ 62.84 $ 60.32 $ 54.98
Y / Y Revenue Growth (TTM) 16.89 % 6.44 % 18.78 % 17.51 % 7.76 %
Year on Year Revenue Growth Overall Ranking # 1956 # 858 # 0 # 0 # 542
Seqeuential Revenue Change (TTM) 5.87 % -3.4 % 4.17 % 9.71 % -3.59 %
Seq. Revenue Growth (TTM) Overall Ranking # 2994 # 1679 # 0 # 0 # 1651


Cumulative Revenue growth Comment
Although Sorrento Therapeutics Inc 's Annual Revenue growth year on year were below company's average 198.35% , Revenue announced in the Jun 30 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 16.89% year on year, from 6.44% in Mar 31 2023.

In the Healthcare sector 305 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 858 to 1956.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 306
Overall # 1956

Revenue TTM Y/Y Growth Statistics
High Average Low
2376.56 %
 198.35 %
-86.24 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 431
S&P 500 # 2994
Cumulative Revenue growth Comment
Although Sorrento Therapeutics Inc 's Annual Revenue growth year on year were below company's average 198.35% , Revenue announced in the Jun 30 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 16.89% year on year, from 6.44% in Mar 31 2023.

In the Healthcare sector 305 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 858 to 1956.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 306
Overall # 1956

Revenue TTM Y/Y Growth Statistics
High Average Low
2376.56 %
198.35 %
-86.24 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 431
S&P 500 # 2994




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SRNEQ's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2023
Xencor Inc50.86%$ 50.863 millions
Xeris Biopharma Holdings Inc 50.19%$ 50.194 millions
Precipio inc 49.77%$ 49.767 millions
Dbv Technologies S a 49.64%$ 49.640 millions
Lensar Inc 49.44%$ 49.440 millions
Shockwave Medical Inc 48.80%$ 48.802 millions
Kyntra Bio Inc 48.69%$ 48.692 millions
Immunocore Holdings Plc48.62%$ 48.621 millions
4d Molecular Therapeutics Inc 47.53%$ 47.531 millions
Vycor Medical Inc 47.22%$ 47.220 millions
Aurinia Pharmaceuticals Inc 47.19%$ 47.189 millions
Standard Biotools Inc 47.00%$ 46.999 millions
Inovio Pharmaceuticals Inc 45.80%$ 45.805 millions
Halozyme Therapeutics Inc 45.07%$ 45.071 millions
Somalogic Inc 44.71%$ 44.712 millions
Castle Biosciences Inc 43.92%$ 43.918 millions
Lantheus Holdings Inc 43.79%$ 43.794 millions
Myomo Inc 43.60%$ 43.602 millions
Recursion Pharmaceuticals Inc 43.56%$ 43.563 millions
Harrow Inc 43.51%$ 43.506 millions
Kymera Therapeutics Inc 43.42%$ 43.417 millions
Zai Lab Limited42.94%$ 42.943 millions
Progyny Inc 42.89%$ 42.890 millions
Outset Medical Inc 42.49%$ 42.487 millions
Biotricity Inc 41.86%$ 41.859 millions
Alnylam Pharmaceuticals Inc 41.78%$ 41.783 millions
Avita Medical Inc 41.01%$ 41.008 millions
Ionis Pharmaceuticals Inc 40.82%$ 40.825 millions
Aim Immunotech Inc 40.00%$ 40.000 millions
Treace Medical Concepts Inc 40.00%$ 39.997 millions


About Sorrento Therapeutics Inc Revenue Growth Rates (SRNEQ), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sorrento Therapeutics Inc (CIK 850261).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-23-041995
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sorrento Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.